DDInter1376 DDInter1847
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a
Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.
Trastuzumab deruxtecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Trastuzumab deruxtecan {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Trastuzumab deruxtecan {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Trastuzumab deruxtecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Trastuzumab deruxtecan may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Trastuzumab deruxtecan may lead to a major life threatening interaction when taken with Upadacitinib